AI pioneer Dr. John E. Kelly III shares insights on building trust, improving data, and driving progress in AI-enabled neurological trials.
Discover how the new McDonald criteria use imaging biomarkers such as the Central Vein Sign (CVS) to make earlier, more accurate MS diagnosis
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
The imaging clinical trials industry continues to grow in the face of unique challenges! To help you keep up, we’ve put together the top trends to...
Advance Parkinson’s research with QMENTA's Imaging Hub: cutting-edge imaging, biomarker insights, and cloud-based tools for early detection and...
Discover how AI enhances medical imaging workflows, boosting accuracy and efficiency. Learn benefits, challenges, and how QMENTA simplifies AI...
QMENTA’s AI Platform Selected for the CAVS-MS Multiple Sclerosis Biomarker...